MacLean P. Nasrallah
A5052402717- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- MRI in cancer diagnosis
- Medical Imaging Techniques and Applications
- Meningioma and schwannoma management
- AI in cancer detection
- Ferroptosis and cancer prognosis
- Brain Tumor Detection and Classification
- Cell Image Analysis Techniques
- Single-cell and spatial transcriptomics
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- MicroRNA in disease regulation
- Brain Metastases and Treatment
- Nanowire Synthesis and Applications
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Neurofibromatosis and Schwannoma Cases
- Cancer, Hypoxia, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Pituitary Gland Disorders and Treatments
- Nanoplatforms for cancer theranostics
University of Pennsylvania
2016-2025
Hospital of the University of Pennsylvania
2015-2025
California University of Pennsylvania
2021-2024
Philadelphia University
2021-2024
Translational Therapeutics (United States)
2022
Universitat de Barcelona
2019
Hospital Sant Joan de Déu Barcelona
2019
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2019
Purdue University West Lafayette
2018
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms resistance.
Abstract Glioblastoma is the most common aggressive adult brain tumor. Numerous studies have reported results from either private institutional data or publicly available datasets. However, current public datasets are limited in terms of: a) number of subjects, b) lack consistent acquisition protocol, c) quality, d) accompanying clinical, demographic, and molecular information. Toward alleviating these limitations, we contribute “University Pennsylvania Imaging, Genomics, Radiomics”...
The remarkable heterogeneity of glioblastoma, across patients and over time, is one the main challenges in precision diagnostics treatment planning. Non-invasive vivo characterization this using imaging could assist understanding disease subtypes, as well risk-stratification planning glioblastoma. current study leveraged advanced analytics radiomic approaches applied to multi-parametric MRI de novo glioblastoma (n = 208 discovery, n 53 replication), discovered three distinct reproducible...
Epidermal growth factor receptor variant III (EGFRvIII) is a driver mutation and potential therapeutic target in glioblastoma. Non-invasive vivo EGFRvIII determination, using clinically acquired multiparametric MRI sequences, could assist assessing spatial heterogeneity related to EGFRvIII, currently not captured via single-specimen analyses. We hypothesize that integration of subtle, yet distinctive, quantitative imaging/radiomic patterns machine learning may lead non-invasively determining...
Fusions involving neurotrophic tyrosine receptor kinase (NTRK) genes are detected in ≤2% of gliomas and can promote gliomagenesis. The remarkable therapeutic efficacy TRK inhibitors, which among the first Food Drug Administration-approved targeted therapies for NTRK-fused gliomas, has generated significant clinical interest characterizing these tumors. In this multi-institutional retrospective study 42 with NTRK fusions, next generation DNA sequencing (n = 41), RNA 1), RNA-sequencing fusion...
Introduction Fluorescence-guided surgery has emerged as a powerful tool to detect, localize and resect tumors in the operative setting. Our laboratory pioneered novel way administer an FDA-approved near-infrared (NIR) contrast agent help surgeons with this task. This technique, coined Second Window ICG, exploits natural permeability of tumor vasculature its poor clearance deliver high doses indocyanine green (ICG) tumors. technique differs substantially from established ICG video angiography...
Abstract Purpose: The clinical utility of plasma cell-free DNA (cfDNA) has not been assessed prospectively in patients with glioblastoma (GBM). We aimed to determine the prognostic impact cfDNA GBM, as well its role a surrogate tumor burden and substrate for next-generation sequencing (NGS). Experimental Design: conducted prospective cohort study 42 newly diagnosed GBM. Plasma was quantified at baseline prior initial resection longitudinally during chemoradiotherapy. association...
Background Imaging of glioblastoma patients after maximal safe resection and chemoradiation commonly demonstrates new enhancements that raise concerns about tumor progression. However, in 30% to 50% patients, these primarily represent the effects treatment, or pseudo‐progression (PsP). We hypothesize quantitative machine learning analysis clinically acquired multiparametric magnetic resonance imaging (mpMRI) can identify subvisual characteristics provide robust, noninvasive signatures...
Bispecific T cell engagers (BiTEs) are bispecific antibodies that redirect cells to target antigen-expressing tumors. We hypothesized BiTE-secreting could be a valuable therapy in solid tumors, with distinct properties mono- or multi-valent strategies incorporating chimeric antigen receptor (CAR) cells. Glioblastomas represent good model for tumor heterogeneity, representing significant therapeutic challenge. detected expression of tumor-associated epidermal growth factor (EGFR), EGFR...
Autologous chimeric antigen receptor (CAR) T cells targeted to epidermal growth factor variant III (CAR T-EGFRvIII) have been developed and administered experimentally treat patients with IDH1 wildtype recurrent glioblastoma (rGBM) (NCT02209376). We report the case of a 59-year-old patient who received single peripheral infusion CAR T-EGFRvIII survived 36 months after disease recurrence, exceeding expected survival for glioblastoma. Post-infusion histopathologic analysis tissue obtained...
Abstract Multi-omic data, i.e., clinical measures, radiomic, and genetic capture multi-faceted tumor characteristics, contributing to a comprehensive patient risk assessment. Here, we investigate the additive value independent reproducibility of integrated diagnostics in prediction overall survival (OS) isocitrate dehydrogenase (IDH)-wildtype GBM patients, by combining conventional deep learning methods. Conventional radiomics features were extracted from pre-operative multi-parametric MRI...
Although genomic anomalies in glioblastoma (GBM) have been well studied for over a decade, its 5-year survival rate remains lower than 5%. We seek to expand the molecular landscape of high-grade glioma, composed IDH-wildtype GBM and IDH-mutant grade 4 astrocytoma, by integrating proteomic, metabolomic, lipidomic, post-translational modifications (PTMs) with transcriptomic measurements uncover multi-scale regulatory interactions governing tumor development evolution. Applying 14 proteogenomic...
Glioblastoma (GBM), a universally fatal brain cancer, infiltrates the and can be synaptically innervated by neurons, which drives tumor progression 1-6 . Synaptic inputs onto GBM cells identified so far are largely short-range glutamatergic 7-9 The extent of integration into brain-wide neuronal circuitry is not well understood. Here we applied rabies virus-mediated retrograde monosynaptic tracing approach 10-12 to systematically investigate circuit human organoids transplanted adult mice. We...
<h3>Objective</h3> To report 2 patients with anti–myelin oligodendrocyte glycoprotein (MOG)-associated encephalitis who were initially misdiagnosed small vessel primary CNS vasculitis. <h3>Methods</h3> Review of symptoms, MRI and neuropathologic features, response to treatment. MOG antibodies determined in serum CSF using a cell-based assay. <h3>Results</h3> Symptoms included fever, headache, progressive mental status changes focal neurologic deficits. studies revealed lymphocytic...